Gilead Sciences: The Speaker Knew the Topic, the Donor Knew the Drug

The Gilead kickback settlement announced in 2025 required Gilead Sciences to pay $202 million over HIV speaker programs that rewarded prescribers with speaking fees, meals and travel. Gilead admitted that providers returned for dinners on subjects they had already been paid to teach. A separate $97 million settlement in 2020 resolved allegations that Gilead used Caring Voice Coalition to pay Medicare copays for Letairis. An employee looking at attendance records and an employee reading foundation funding requests could see different ways the company’s spending connected to government-paid prescriptions.

The Justice Department’s April 29, 2025 announcement says the government joined a private whistleblower case under the False Claims Act. In these pharmaceutical fraud cases, the government alleged that payments violating the Anti-Kickback Statute led to false claims for government-paid prescriptions under the False Claims Act.

What Gilead Admitted About Its HIV Speaker Programs

Gilead admitted that its policies and procedures failed to prevent sales representatives and regional directors from improperly providing speaking fees, meals and travel to induce prescriptions.

The government’s case covered conduct from January 2011 through November 2017 and named six HIV drugs: Stribild, Genvoya, Complera, Odefsey, Descovy and Biktarvy. The speaker programs were part of Gilead’s marketing efforts. A healthcare provider would present a company-prepared slide deck about a drug or an HIV disease topic and lead a discussion with other providers. Many events took place over dinner.

That format gave a sales event the appearance of professional education. The government alleged that the programs were supposed to offer education and modest meals, but instead delivered expensive dinners, repeated presentations and trips chosen partly for the destination. The audience’s attendance history made the educational explanation harder to sustain.

The Audience Had Already Taught the Class

Gilead admitted that more than 250 prescribers attended dinner programs on the same topic at least three times within six months. More than 80 attended five or more such programs. Providers paid to speak on a subject also returned as audience members for that same subject. In some instances, the return visit came less than two weeks after they had spoken.

The New York attorney general’s account describes a nurse practitioner who attended 75 dinner programs and often brought a sibling who did not prescribe Gilead HIV drugs. It also describes a group of ten Manhattan doctors who spoke at or attended approximately 384 dinner programs with others in the group. More than 300 of those events featured one of those doctors as the speaker.

The same people could move from the lectern to the dinner table while the subject stayed the same. The value of the next invitation was easier to understand from the meal than from the lesson.

Dinner and Travel Were Part of the Payment

Gilead admitted holding 157 HIV speaker programs at the James Beard House, where dinner typically included approximately six courses with alcoholic beverage pairings. Sales representatives organized programs at expensive restaurants across the country. Medical education came with a tasting menu.

Gilead also admitted covering long-distance speaker travel to Hawaii, Miami and New Orleans. Sometimes the speaker asked to be booked in the destination city. For an employee arranging the trip, the travel request could explain something the event’s title did not: why that speaker was going to that place.

The District of Columbia attorney general’s release reported that 548 healthcare providers received more than $23.7 million in honoraria, in addition to meals and travel. The speaking fee was only one part of what providers received.

Gilead HIV Speaker Programs and Prescribing Return on Investment

The return on investment of Gilead’s HIV speaker programs shows up in prescribing, when speaker payments and government-paid prescriptions sit side by side. Gilead’s admissions supply a particularly clear example:

The company paid the speaking fees. Government health care programs paid for the prescriptions. A sales employee familiar with a prescriber’s volume can recognize why the payment record matters alongside the event calendar.

The Justice Department said Medicare typically paid well over a thousand dollars for a one-month supply of Complera, and significantly more for many of the other Gilead HIV drugs. The New York attorney general’s account identifies Medicare, TRICARE, Medicaid and the AIDS Drug Assistance Program as programs covered by the settlement.

The government alleged that providers receiving the improper benefits prescribed Gilead’s drugs and caused federal programs to pay for prescriptions influenced by those kickbacks. Taxpayers paid the bill.

The Policies Failed to Stop the Payments

Gilead’s admission about failed controls reaches the people operating the program: sales representatives and regional directors. The company had policies. It also had repeated attendance, expensive meals and travel benefits that those policies failed to stop. For a compliance or sales insider, the difference between the written rule and the recurring practice is the part of the case they may know firsthand.

What Gilead’s Letairis Copay Settlement Alleged

Gilead’s Letairis copay settlement concerned allegations that the company used Caring Voice Coalition to cover Medicare patients’ share of the price of its own drug. The September 23, 2020 announcement described payments through a foundation, product-specific reports and referrals that generated Medicare claims.

Letairis treats pulmonary arterial hypertension. A patient receiving a drug under Medicare Part D may owe a copay, coinsurance or deductible. The government explained that this patient share was intended partly to restrain health care costs, including the prices manufacturers could demand. Its allegation was that Gilead used foundation assistance to remove a price barrier for thousands of Medicare patients taking Letairis.

That is another form of paying for prescriptions through an intermediary. In the government’s account, Gilead could support the patient’s copay while Medicare received a claim for the drug. The foundation’s role mattered because it stood between the manufacturer’s payment and the patient’s purchase.

The Donor Received Reports About Its Own Drug

From June 15, 2007, through December 31, 2010, Gilead allegedly obtained information showing how many Letairis patients Caring Voice Coalition had helped, how much it had spent on them and how much it expected to spend on them in the future. Funding requests, telephone calls and written reports carried that information back to Gilead.

The government alleged that Gilead used those figures to budget future payments covering copays for Letairis patients, excluding patients taking competing manufacturers’ pulmonary arterial hypertension drugs. It also alleged that Gilead knew it should not receive or use the foundation’s Letairis spending data.

The important detail is the product name attached to the information. A report about Letairis patients and expected Letairis spending gave the donor a way to plan support around its own sales. According to the government, Gilead then referred Medicare patients to the foundation to generate revenue, and those referrals resulted in Medicare claims for Letairis.

The alleged arrangement linked a donation budget to a particular manufacturer’s patients. An employee handling the funding request could see that link before anyone outside the arrangement saw a Medicare claim.

Patient Assistance and the Price of Letairis

The government alleged that Gilead knew its Letairis prices could prevent patients from buying the drug and used foundation payments to overcome that obstacle. In the settlement announcement, prosecutors said Gilead had raised the drug’s price by more than seven times the rate of overall U.S. inflation during the covered period.

The alleged scheme linked the price to the assistance: the company set the drug’s price, helped cover the patient’s share through a foundation and generated claims paid by Medicare. The patient’s immediate bill and the government’s bill moved through different hands.

The Same Foundation Pattern in Other Pulmonary Arterial Hypertension Cases

United Therapeutics’ separate copay case involved allegations that the manufacturer used foundation spending data for its drugs to decide how much to donate. The government also alleged that the company excluded needy Medicare patients from a free-drug program available to other financially needy patients.

In Actelion’s case, the government alleged that the manufacturer received information even after the foundation warned the company against receiving it. The recurring issue was what a donor learned about assistance for its own products and how that knowledge shaped its funding. Gilead’s alleged use of patient counts, spending reports and forecasts fits that specific pattern.

What Evidence Is Needed to Prove Fraud?

The evidence lies in connecting the payments, the company’s decisions and the government-paid prescriptions. We work with you to make those connections from the records and business practices you know.

A speaker-program employee may know why a provider was chosen, who kept receiving invitations and how a trip was booked. A patient-assistance or finance employee may know which product’s patients appeared in a funding request and how the requested amount became the next donation. Those are different views of how a manufacturer’s payment reached the prescription.

Our work with pharmaceutical whistleblowers starts with that knowledge of the business. We connect what you saw to the payments, the decisions behind them and the government claims. The value of an insider’s account is often the explanation that makes separate records tell the same story.

How Much Money Do Pharmaceutical Whistleblowers Get for Exposing Fraud?

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers. The Gilead speaker resolution grew out of a private whistleblower case that the government joined. The opportunity begins with the conduct and the records you understand, whether your view comes from sales events or patient-assistance funding.

You Know Why the Company Paid

If you saw repeat dinner invitations, speaker payments tied to prescribing or foundation budgets built around one drug, speak to one of our whistleblower experts about the payments you saw. We build your strongest pharmaceutical whistleblower case with you, bring in pharmaceutical kickback whistleblower lawyers who understand sales programs and patient-assistance arrangements, and remain your partners throughout the case.